Comparative effectiveness of non-cisplatin first-line therapies for metastatic urothelial carcinoma: phase 2 IMvigor210 study versus US patients treated in the Veterans …
N Vander Velde, A Guerin, R Ionescu-Ittu, S Shi… - European Urology …, 2019 - Elsevier
Background First-line treatments for cisplatin-ineligible patients with metastatic urothelial
carcinoma (mUC) include carboplatin-based chemotherapy and checkpoint inhibitors such …
carcinoma (mUC) include carboplatin-based chemotherapy and checkpoint inhibitors such …
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: outcomes by prior number of regimens
Background Patients with metastatic urothelial carcinoma (mUC) who progress after
platinum-based chemotherapy have had few treatment options and uniformly poor …
platinum-based chemotherapy have had few treatment options and uniformly poor …
[HTML][HTML] 699P Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival …
JE Rosenberg, MD Galsky, AV Balar… - Annals of …, 2021 - annalsofoncology.org
Background Cisplatin-based chemotherapy is the standard of care for first-line (1L)
metastatic urothelial carcinoma (mUC), although many patients (pts) are ineligible for …
metastatic urothelial carcinoma (mUC), although many patients (pts) are ineligible for …
[HTML][HTML] Second-line systemic treatment for metastatic urothelial carcinoma: A network meta-analysis of randomized phase III clinical trials
HS Yoon, C Kwak, HH Kim, HS Kim, JH Ku - Frontiers in Oncology, 2019 - frontiersin.org
Purpose: We aimed to evaluate and compare relative impacts of various second-line
treatments on overall survival (OS) in metastatic urothelial carcinoma (mUC). Method: A …
treatments on overall survival (OS) in metastatic urothelial carcinoma (mUC). Method: A …
Atezolizumab in metastatic urothelial carcinoma outside clinical trials: focus on efficacy, safety, and response to subsequent therapies
Background Little is known about the outcomes, safety, and response to subsequent
therapies of patients with metastatic urothelial carcinoma (mUC) treated with atezolizumab …
therapies of patients with metastatic urothelial carcinoma (mUC) treated with atezolizumab …
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: results of real-life experiences
D Tural, ÖF Ölmez, AT Sümbül, M Artaç, N Özhan… - European urology …, 2021 - Elsevier
Background Atezolizumab (ATZ) has demonstrated antitumor activity and manageable
safety in previous studies in patients with locally advanced or metastatic platinum-resistant …
safety in previous studies in patients with locally advanced or metastatic platinum-resistant …
Abstract CT042: Atezolizumab (atezo)+ platinum/gemcitabine (plt/gem) vs placebo+ plt/gem in patients (pts) with previously untreated locally advanced or metastatic …
MD Galsky, JÁ Arranz, E Grande, M De Santis, ID Davis… - Cancer Research, 2021 - AACR
Abstract Background: The IMvigor130 primary analysis demonstrated a statistically
significant progression-free survival (PFS) benefit and encouraging OS with atezo+ plt/gem …
significant progression-free survival (PFS) benefit and encouraging OS with atezo+ plt/gem …
Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study …
AV Balar, R Dreicer, Y Loriot, JL Perez-Gracia… - 2018 - ascopubs.org
4523 Background: Platinum-based chemotherapy is a standard first-line approach for mUC,
but many pts are ineligible for cisplatin, and progression is common. Atezo (anti–PD-L1) was …
but many pts are ineligible for cisplatin, and progression is common. Atezo (anti–PD-L1) was …
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Background Atezolizumab can induce sustained responses in metastatic urothelial
carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab …
carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab …
The evolving treatment landscape of metastatic urothelial cancer
G Roviello, M Santoni, GP Sonpavde… - Nature Reviews …, 2024 - nature.com
Cisplatin-based chemotherapy is currently the first-line standard of care for patients with
metastatic urothelial cancer (mUC); however, up to 50% of patients are ineligible for …
metastatic urothelial cancer (mUC); however, up to 50% of patients are ineligible for …